3-氨基苯硼酸 | 30418-59-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基苯硼酸
• 中文别名: 间氨基苯硼酸
• 英文名称: 3-Aminophenylboronic acid
• 英文别名: 3-aminobenzeneboronic acid；m-aminophenylboronic acid；3-APBA；(3-aminophenyl)boronic acid
• CAS: 30418-59-8
• 化学式: C₆H₈BNO₂
• mdl: MFCD00007755
• 分子量: 136.946
• InChiKey: JMZFEHDNIAQMNB-UHFFFAOYSA-N

物化性质

• 熔点：
  225 °C
• 沸点：
  376.0±44.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，也不存在已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  0.86
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2931900090
• 储存条件：
  本品应密封于4℃保存，而半硫酸盐则应在室温下干燥保存。

SDS

Name:	3-Aminophenylboronic Acid Monohydrate 98% Material Safety Data Sheet
Synonym:	3-Aminobenzeneboronic Acid
CAS:	30418-59-8

Section 1 - Chemical Product MSDS Name:3-Aminophenylboronic Acid Monohydrate 98% Material Safety Data Sheet
Synonym:3-Aminobenzeneboronic Acid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
30418-59-8	3-Aminophenylboronic Acid Monohydrate	98%	250-189-0

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 30418-59-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 94 - 97 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H8BNO2.H2O
Molecular Weight: 154.97

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, boron oxides.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 30418-59-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Aminophenylboronic Acid Monohydrate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 30418-59-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 30418-59-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 30418-59-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用于医药中间体

反应信息

• 作为反应物：
  描述：

  3-氨基苯硼酸 在 氧气 、 N,N-二异丙基乙胺 作用下， 以 丙酮 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 65.0h， 以32%的产率得到3-氨基苯酚
  参考文献：
  名称：

  来自量子点的皮秒电子转移可实现硼酸的普遍有效的有氧氧化

  摘要：

  使用CdSe纳米晶体量子点（QDs）作为光氧化还原催化剂，揭示了一般可见光介导的硼酸的好氧氧化。该方案要求温和的反应条件和低的催化剂负载量（低至10 ppm），并能耐受各种官能团。产生的苯酚和脂族醇以高至高收率生产，营业额高达> 62000。使用超快速瞬态吸收和发光光谱探测了反应机理。证明了存在快速的350 ps初始电子传输，然后是空穴传输。

  DOI：

  10.1021/acscatal.8b01078
• 作为产物：
  描述：

  苯硼酸 在 barium dihydroxide 、 iron hydroxide 、 水 、 硝酸 、 尿素 作用下， 生成 3-氨基苯硼酸
  参考文献：
  名称：

  Seaman; Johnson, Journal of the American Chemical Society, 1931, vol. 53, p. 713

  摘要：

  DOI：
• 作为试剂：
  描述：

  异硫氰酸荧光素酯 、 3-氨基苯硼酸 、 三乙胺 在 水 、 3-氨基苯硼酸 、 二氯甲烷 、 甲醇 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Glycated proteins assay

  摘要：

  一种针对糖基化蛋白质的溶液相测定方法，例如对糖基化血红蛋白和血浆可溶性糖基化蛋白进行测定。该方法将测定样品与含有硼酸基团的光致发光或化学发光标记化合物反应，该化合物与糖基化蛋白质具有选择性反应。在偏好的波长下，标记化合物的发光被其与糖基化蛋白质的结合所选择性猝灭。发光的猝灭给出了糖基化蛋白质的糖化程度的测量值。

  公开号：

  US05877025A1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Scope and selectivity in palladium-catalyzed directed C–H bond halogenation reactions
  作者：Dipannita Kalyani、Allison R. Dick、Waseem Q. Anani、Melanie S. Sanford

  DOI：10.1016/j.tet.2006.06.075

  日期：2006.12

  Palladium-catalyzed ligand directed C–H activation/halogenation reactions have been extensively explored. Both the nature of the directing group and the substitution pattern on the arene ring of the substrate lead to different reactivity profiles, and often different and complementary products, in the presence and absence of the catalyst.

  钯催化的配体定向的C–H活化/卤化反应已得到广泛研究。在存在和不存在催化剂的情况下，导向基团的性质和底物的芳环上的取代图案均导致不同的反应性分布，并且常常导致不同的和互补的产物。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Tuning the Biological Activity of RGD Peptides with Halotryptophans
  作者：Isabell Kemker、David C. Schröder、Rebecca C. Feiner、Kristian M. Müller、Antoine Marion、Norbert Sewald

  DOI：10.1021/acs.jmedchem.0c01536

  日期：2021.1.14

  halogenation by halogenases or incorporation of haloindoles using tryptophan synthase. Introduction of these Trp derivatives into RGD peptides as a benchmark system was performed to investigate their influence on bioactivity. Halotryptophan-containing RGD peptides display increased affinity toward integrin αvβ3 and enhanced selectivity over integrin α5β1. In addition, bromotryptophan was exploited as a platform

  使用通过卤化酶的酶促卤化或使用色氨酸合酶掺入卤代吲哚来合成在吲哚部分具有不同取代基的1-和d-卤代色氨酸的阵列。将这些Trp衍生物引入RGD肽作为基准系统以研究其对生物活性的影响。含Halotryptophan-RGD肽显示增加的亲和力朝向整合素α v β 3和增强的过整合素α选择性5 β 1。另外，铃木色氨酸被铃木-宫浦交叉耦合（SMC）开发为后期多样化的平台，从而产生了新的自然的联芳基序。这些肽显示出增强的朝向α亲和力v β 3，良好的亲和力，以α v β 8，和显着的选择性超过α 5 β 1和α IIB β 3，同时具有荧光性质。在体外证明了其作为探针的可行性。进行了广泛的分子动力学模拟，以阐明这些后期多样化的环状RGD肽的NMR和高效液相色谱（HPLC）数据，并进一步表征其构象偏好。
• Trisubstitution of pyridine through sequential and regioselective palladium cross-coupling reactions affording analogs of known GPR54 antagonists
  作者：Christelle Doebelin、Patrick Wagner、Isabelle Bertin、Frédéric Simonin、Martine Schmitt、Frédéric Bihel、Jean-Jacques Bourguignon

  DOI：10.1039/c3ra41985a

  日期：——

  large spectrum of applications, poly-functionalized pyridines remain an attractive challenge in modern organic chemistry. We describe the poly-functionalization of halopyridines through a series of sequential and regioselective palladium-catalyzed cross-coupling reactions (Suzuki–Miyaura, Sonogashira and Buchwald–Hartwig reactions). This strategy was applied to the synthesis of several analogs of single

  由于其广泛的应用范围，多官能吡啶在现代有机化学中仍然是一个有吸引力的挑战。我们通过一系列顺序和区域选择性钯催化的交叉偶联反应（Suzuki-Miyaura，Sonogashira和Buchwald-Hartwig反应）描述了卤代吡啶的多官能化。将该策略应用于单一非肽类已知GPR54拮抗剂的几种类似物的合成。

表征谱图